Metagenomi Therapeutics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+23.5% +$7M
$-23M
Free Cash Flow↑+74.6% +$249K
$-85K
Investing Cash Flow↑+13.4% +$4M
$32M
Financing Cash Flow
$74K
Capex↓-74.6% -$249K
$85K
Stock-Based Comp↓-21.0% -$718K
$3M
D&A↓-11.0% -$161K
$1M
SBC Allocated Expense↓-21.0% -$718K
$3M
SBC Unrecognized Cost
$18M